⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGVN News
Longeveron Inc. Common Stock
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
globenewswire.com
LGVN
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
LGVN
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
globenewswire.com
LGVN
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
globenewswire.com
LGVN
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
globenewswire.com
LGVN
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
globenewswire.com
LGVN